National Cancer Institute®
Last Modified: March 1, 2002
UI - 11748366
AU - Kim TS; Seong DH; Ro JY
TI - Small cell carcinoma of the ureter with squamous cell and transitional cell carcinomatous components associated with ureteral stone.
SO - J Korean Med Sci 2001 Dec;16(6):796-800
AD - Department of Pathology, Inha University College of Medicine, Inchon, Korea. email@example.com
We report a case of primary small cell carcinoma of the ureter with squamous cell and transitional cell carcinomatous components associated with ureteral stone, which is unique in that the patient has remained free of tumor recurrence for 36 months after the surgery without adjuvant chemotherapy or radiotherapy. A 60-yr-old man presented himself with a right flank pain. Computed tomography revealed an ill-defined mass and a stone in the lower one third of the right ureter, and hydronephroureterosis above the stone-impacted site. The patient underwent right nephroureterectomy and stone removal. Upon gross examination, a 3.8 x 1.8 x 1.2 cm white and partly yellow mass was noted in the anterior part of the ureter, resulting in indentation of the ureteral lumen on the posterior side. Light microscopic examination revealed that the mass was mainly composed of small cell carcinoma, and partly squamous cell and transitional cell carcinomatous components. The overlying ureteral mucosa and renal pelvis also contained multifocal dysplastic transitional epithelium and transitional cell carcinoma in situ. There was no vascular invasion, and the surgical margins were free of tumor. The small cell carcinomatous component was positive for chromogranin, neuron specific enolase, synaptophysin, and pancytokeratin but negative for high molecular-weight cytokeratin (K-903) by immunohistochemistry.
UI - 11797592
AU - Altwein JE
TI - [Dysuria. Typical symptoms for proper diagnosis]
SO - MMW Fortschr Med 2001 Nov 26;143 Suppl():121-30; quiz 131-2
AD - Urologische Abteilung, Krankenhaus der Barmherzigen Bruder, Munchen.
UI - 11685715
AU - Gow KW; Hoffer F; Lasater O; Shochat SJ
TI - Intraureteral Wilms tumor.
SO - J Pediatr Surg 2001 Nov;36(11):1729-30
AD - Department of Surgery & Radiology, St Jude Children's Research Hospital, Memphis, TN, USA.
UI - 11868382
AU - Kakoi N; Miyajima A; Motizuku T; Mizuguchi Y; Asano T; Hayakawa M
TI - [Carcinosarcoma of the renal pelvis and ureter: a case report]
SO - Hinyokika Kiyo 2002 Jan;48(1):29-32
We report a case of carcinosarcoma of the renal pelvis and ureter arising in an 89-year-old man who presented at our hospital with gross hematuria. Abdominal computed tomography, excretory pyelography, and retrograde pyelography demonstrated that left hydronephrosis was caused by an ureteral tumor. Left urine cytology indicated transitional cell carcinoma. The patient underwent chemotherapy and radiation therapy. However, gross hematuria recurred, and the patient underwent left nephroureterectomy. The surgical specimen showed carcinosarcoma in the renal pelvis and ureter histologically. He has been free of cancer for 1.5 years.
UI - 11550496
AU - Gyurkovics E; Nagy Z; Pajor L; Sipos B; Szucs M; Harsanyi L
TI - [Successfully operated infraperitoneal hemangiopericytoma infiltrating the left ureter]
SO - Magy Seb 2001 Aug;54(4):253-5
AD - Semmelweis Egyetem Altalanos Orvostudomanyi Kar I. sz. Sebeszeti Klinika, 1082 Budapest, Ulloi ut 78. firstname.lastname@example.org
Hemangiopericytoma is a very rare tumour originating from the lining cells of small vessels. Despite benign histology it is clinical presentation similar to malignancy. There are only less than hundred cases reported sporadically in the literature. Authors report a case and successful radical removal of an infraperitoneal hemangiopericytoma infiltrating the left ureter. The literature of this strange, rare pathology is also analysed in the article.
UI - 11844814
AU - Vaughn DJ; Broome CM; Hussain M; Gutheil JC; Markowitz AB
TI - Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.
SO - J Clin Oncol 2002 Feb 15;20(4):937-40
AD - University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA. email@example.com
PURPOSE: We evaluated the efficacy and toxicity of weekly paclitaxel in patients with previously treated advanced urothelial cancer. PATIENTS AND METHODS: Patients with urothelial cancer who had received one prior systemic chemotherapy regimen for advanced disease and had evidence of disease progression were eligible for enrollment. Patients received paclitaxel 80 mg/m(2) by 1-hour intravenous infusion weekly. A cycle of therapy consisted of four weekly treatments. RESULTS: The study enrolled 31 patients. Mean age was 66 years, and 45% of patients had three or more involved metastatic sites. Only 26% of patients had responded to prior chemotherapy. The median number of cycles delivered was three (range, one to eight) at a mean weekly paclitaxel dose of 79 mg/m(2). Three patients achieved a partial response (10%; 95% confidence interval, 0% to 20%). Median time to progression was 2.2 months, and median overall survival time was 7.2 months. Therapy was well tolerated with minimal hematologic toxicity. Grade 3 nonhematologic toxicities were also uncommon. CONCLUSION: Although the overall response rate to weekly paclitaxel in patients with previously treated advanced urothelial cancer was modest, the chemotherapy-refractory nature of the study population should be considered.
UI - 11111187
AU - Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Nishimura K; Takaha N;
TI - Takahara S; Okuyama A Bacillus Calmette-Guerin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract.
SO - Eur Urol 2000 Dec;38(6):701-4;discussion 705
AD - Department of Urology, Osaka University Medical School, Suita City, Osaka, Japan. firstname.lastname@example.org
OBJECTIVES: The aim of this study is to evaluate the efficacy and safety of intrarenal bacillus Calmette-Guerin (BCG) instillation as a treatment for transitional cell carcinoma in situ (CIS) of the upper urinary tract. METHODS: Diagnostic criteria of upper urinary tract CIS were (1) positive urinary cytology, (2) negative multiple random biopsy of the bladder and prostatic urethra, (3) negative radiographic findings in the upper urinary tract and (4) two serial positive cytologies in selective ipsilateral urine sampling from the pyeloureteral system. Eleven patients diagnosed as having upper urinary tract CIS were enrolled in this study. Thus, 11 renal units were treated with BCG instillation. After placing a 6-french Double-J stent, BCG (80 mg) in 40 ml saline was instilled into the bladder weekly, 6 times in total as one course. RESULTS: At the end of one course, 9 cases showed negative urinary cytology. Among these 9 cases, 2 showed recurrence in the upper urinary tract after 4 months and 8 months of disease-free interval, respectively. These 2 cases have received an additional course of BCG instillation, but the urinary cytology did not normalize. Mean recurrence-free time was 19.6 months. Of the other 7 cases who responded to the first course of instillation, 6 cases were alive with no evidence of the disease. The remaining patient died of rectal cancer with no evidence of transitional cell carcinoma (TCC). Of the 2 cases who showed positive urinary cytology even after the first course, 1 underwent nephroureterectomy. The other case was diagnosed as having malignant lymphoma 3 months after the end of this instillation therapy, and he died of malignant lymphoma. As side effects, 8 cases (72.7%) showed bladder irritability, and 4 presented fever higher than 38 degrees C. However, no patient needed antitubercular treatment. CONCLUSION: As for the short-term response, BCG instillation for the treatment of upper urinary tract CIS is considered to be effective and safe. Longer follow-up and further experience with this treatment are required.
UI - 11888084
AU - Witte D; Truong LD; Ramzy I
TI - Transitional cell carcinoma of the renal pelvis the diagnostic role of pelvic washings.
SO - Am J Clin Pathol 2002 Mar;117(3):444-50
AD - Department of Pathology, Baylor College of Medicine and the Methodist Hospital, Houston, TX 77030, USA.
One hundred renal pelvic washings were reviewed blindly for 12 cytologic features. Of 52 washings with tissue confirmation, the cytologic diagnosis suggestive of or positive for transitional cell carcinoma (TCC) was made in 36 cases; 11 were negative, and 5 were unsatisfactory. Of 36 positive washings, histology confirmed the TCC diagnosis in 35 but revealed only reactive changes in 1. Of 11 negative washings, 9 were histologically negative for TCC, and 2 were positive for high-grade TCC. Among 48 washings without tissue confirmation, 33 were negative for TCC or showed reactive changes, 12 were negative for high-grade dysplasia or malignancy, but low-grade TCC could not be ruled out, 1 was suggestive of malignancy, and 2 were unsatisfactory. Clinical follow-up revealed no TCC. Predictive cytologic features of high-grade TCC were high nuclear/cytoplasmic ratio, isolated cells, anisonucleosis, nuclear hyperchromasia, and coarse chromatin; for low-grade they were presence of more than 5 papillary groups, cellular overlapping, anisonucleosis, and hyperchromasia. The sensitivity and specificity for the cytologic diagnosis were 89% and 97% for high-grade TCC and 100% and 78% for low-grade TCC, respectively. Renal pelvic washings can be used to accurately diagnose TCC of the renal pelvis. The positive predictive value for high-grade TCC is 93%, but for low-grade tumors it is 43%.
UI - 11851772
AU - Hisataki T; Takahashi A; Taguchi K; Shimizu T; Suzuki K; Takatsuka K;
TI - Iwaki H Sarcomatoid transitional cell carcinoma originating from a duplicated renal pelvis.
SO - Int J Urol 2001 Dec;8(12):704-6
AD - Department of Urology, Sunagawa City Medical Center, Sunagawa, Japan. email@example.com
A case of sarcomatoid transitional cell carcinoma of the renal pelvis is reported. It was distinguished from carcinosarcoma by immunohistochemical study. The tumor was difficult to distinguish from a renal parenchymal tumor in imaging studies because it originated from a duplicated renal pelvis.
UI - 11868087
AU - Bellin MF; Springer O; Mourey-Gerosa I; Coumbaras J; Chartier-Kastler E;
TI - Delcourt A; Beigelman C; Grenier P CT diagnosis of ureteral fibroepithelial polyps.
SO - Eur Radiol 2002 Jan;12(1):125-8
AD - Department of Radiology, Groupe Hospitalier Pitie-Salpetriere, 75651 Paris, France. firstname.lastname@example.org
We report a case of fibroepithelial polyp of the ureter with serial CT examinations. Progressive growth of the fibroepithelial polyp was documented by CT within a period of 62 months. Excretory phase contrast-enhanced CT images accurately contributed to the diagnosis of ureteral fibroepithelial polyp and allowed limited surgical resection. Accurate imaging assessment of ureteral fibroepithelial polyps is essential for a conservative surgical approach and/or observation alone.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.